Burrage Matthew K, Ferreira Vanessa M
Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Cardiovasc Diagn Ther. 2020 Jun;10(3):610-624. doi: 10.21037/cdt-20-165.
Contemporary cancer therapy has resulted in significant survival gains for patients. However, many current and emerging cancer therapies have an associated risk of cardiotoxicity, either acutely or later in life. Regular cardiac screening and surveillance is recommended for patients undergoing treatment for cancer, with emphasis on the early detection of cardiotoxicity before irreversible complications develop. Cardiovascular magnetic resonance imaging is able to accurately assess cardiac structure, function, and perform advanced myocardial tissue characterisation, including perfusion, features which may facilitate the diagnosis and management of cardiotoxicity in cancer survivors. This review outlines the current standards for the diagnosis and screening of cardiotoxicity, with particular focus on current and future applications of cardiovascular magnetic resonance imaging.
当代癌症治疗已使患者的生存率显著提高。然而，许多现有的和新出现的癌症治疗方法都伴有急性或后期心脏毒性风险。建议对接受癌症治疗的患者进行定期心脏筛查和监测，重点是在不可逆并发症发生之前早期发现心脏毒性。心血管磁共振成像能够准确评估心脏结构、功能，并对心肌组织进行高级特征分析，包括灌注，这些特征可能有助于癌症幸存者心脏毒性的诊断和管理。本综述概述了心脏毒性诊断和筛查的当前标准，特别关注心血管磁共振成像的当前和未来应用。
